Ian Collins,Michael Lainchbury,Thomas Peter Matthews,John Charles Reader
申请号：
US14693307
公开号：
US20150225372A1
申请日:
2015.04.22
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor (b) a DNA damaging agent (c) an antimetabolite or thymidylate synthase (TS) inhibitor (d) a microtubule targeted agent and (e) ionising radiation.
